Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Toxicity, efficacy, and clinical management of bispecific antibodies in routine clinical practice: A real-world geltamo study in B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MBMariana Bastos‐OreiroGIGloria IacoboniPMPablo Manresa Manresa

Discussion

Loading...

Member takes

Overview

Retrospective study finds response rates and toxicity profiles of bispecific antibodies in B-cell lymphoma, suggesting implications for outpatient management.

Key Points

  • To evaluate the toxicity, efficacy, and clinical management of bispecific antibodies in routine care for B-cell lymphoma.
  • Conducted a retrospective, multicenter study
  • Included adults with relapsed/refractory B-cell lymphoma treated with commercial bispecific antibodies
  • Analyzed patient demographics, toxicity, and clinical management approaches
  • Among 168 patients, response rates were 43% for large B-cell lymphoma and 75% for follicular lymphoma
  • Tocilizumab was administered in 31% of patients with cytokine release syndrome
  • Progression-free survival was 4.0 months for large B-cell lymphoma and 17 months for follicular lymphoma

Cite This Study

Bastos‐Oreiro et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d097https://doi.org/10.1182/blood-2025-2732
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need2025
  4. 4CD20×CD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis2025 · 4 citations
  5. 5Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas2025 · 1 citations